Home About Domain Investment Team Portfolio Companies News Contact Us
 
 
Portfolio Company News

 
  CELATOR PRESENTS DATA ON THE ACTIVITY OF CPX-351 AGAINST LEUKEMIA AT THE EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS  
6/8/2009
more
 
 
 
 
  RELAXIN FOR AHF IS THE STRONGEST PREDICTOR OF IMPROVED LONGER-TERM OUTCOMES FOLLOWING HOSPITAL DISCHARGE WHEN COMPARED TO OTHER VARIABLES  
6/1/2009
more
 
 
 
 
  RESULTS AND ADDITIONAL ANALYSES FROM EFFICACY AND SAFETY STUDY OF CORTHERA’S RELAXIN IN ACUTE HEART FAILURE TO BE PRESENTED AT HEART FAILURE CONGRESS  
5/28/2009
more
 
 
 
 
  CLOVIS ONCOLOGY RAISES $145 MILLION IN START-UP FINANCING  
5/21/2009
more
 
 
 
 
  CELATOR® PHARMACEUTICALS INITIATES RESEARCH AGREEMENT WITH CEPHALON, INC.  
5/21/2009
more
 
 
 
 
  CELATOR® PHARMACEUTICALS TO PRESENT AT 2009 BIO INTERNATIONAL CONVENTION  
5/13/2009
more
 
 
 
 
  ALTEA THERAPEUTICS ANNOUNCES SENIOR R&D MANAGEMENT APPOINTMENTS  
5/5/2009
more
 
 
 
 
  EVOKE PHARMA, INC. INITIATES PHASE 2B METOCLOPRAMIDE INTRANASAL TRIAL (MINT) IN PATIENTS WITH DIABETIC GASTROPARESIS  
5/5/2009
more
 
 
 
 
  CELATOR® PHARMACEUTICALS PRESENTS NEW DATA ON CPX-351 and CPX-1 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH  
4/22/2009
more
 
 
 
 
  VENTIRX INITIATES PHASE I TRIAL OF VTX-1463, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ALLERGIC RHINITIS  
4/16/2009
more
 
 
 
 
  SANOFI-AVENTIS TO ACQUIRE BIPAR SCIENCES  
4/15/2009
more
 
 
 
 
  ALTEA THERAPEUTICS ANNOUNCES AGREEMENT WITH AMYLIN AND LILLY FOR AN INVESTIGATIONAL TRANSDERMAL EXENATIDE  
4/1/2009
more
 
 
 
 
  RESULTS FROM STUDY SHOW PROMISING EFFICACY AND SAFETY RESULTS FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE  
3/29/2009
more
 
 
 
 
  MARINUS PHARMACEUTICALS, INC. ANNOUNCES POSITIVE RESULTS OF ITS PHASE 2 CLINICAL TRIAL OF GANAXOLONE AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSE  
3/3/2009
more
 
 
 
 
  ASCENTA THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY RESULTS WITH AT-101 IN DOCETAXEL REFACTORY PROSTATE CANCER  
2/27/2009
more
 
 
 
 
  NOVALAR ANNOUNCES THE LAUNCH OF ORAVERSE™ THE FIRST DENTAL ANESTHESIA REVERSAL AGENT  
2/27/2009
more
 
 
 
 
  MERITAGE PHARMA INITIATES PHASE 2B CLINICAL TRIAL OF ORAL VISCOUS BUDESONIDE FOR PEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS  
1/22/2009
more
 
 
 
 
  LEUKEMIA & LYMPHOMA SOCIETY AND CELATOR ANNOUNCE PARTNERSHIP TO ACCELERATE DEVELOPMENT OF CPX-351 FOR AML  
1/22/2009
more
 
 
 
 
  VENTIRX PHARMACEUTICALS COMMENCES PHASE I CLINICAL TRIAL OF VTX-2337, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ONCOLOGY  
12/4/2008
more
 
 
 
 
  CELATOR PHARMACEUTICALS TO PRESENT AT PIPER JAFFRAY HEALTH CARE CONFERENCE and MID-ATLANTIC CAPITAL CONFERENCE  
11/25/2008
more
 
 
 
 
  CELATOR PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 STUDY WITH CPX-351  
11/18/2008
more
 
 
 
 
  INTERIM ANALYSIS OF TOP-LINE DATA FROM PHASE II/III STUDY SHOWS FAVORABLE EFFICACY & SAFETY FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE  
11/10/2008
more
 
 
 
 
  BIPAR SCIENCES' LEAD COMPOUND SELECTED AS TOP 10 ONCOLOGY DRUG CANDIDATE  
10/28/2008
more
 
 
 
 
  MARINUS COMPLETES TWO PHASE 2 MILESTONES FOR GANAXOLONE IN EPILEPSY  
10/7/2008
more
 
 
 
 
  ALIMERA REPORTS RESULTS FROM THE SIX-MONTH INTERIM READOUT OF THE HUMAN PK ILUVIEN™ STUDY  
10/1/2008
more
 
 
 
 
  OCEANA THERAPEUTICS COMMENCES OPERATIONS AFTER COMPLETING SERIES A FINANCING ROUND  
9/29/2008
more
 
 
 
 
  GI DYNAMICS ANNOUNCES SHORT-TERM WEIGHT LOSS RESULTS IN MORBIDLY OBESE PATIENTS  
9/26/2008
more
 
 
 
 
  GI DYNAMICS ANNOUNCES DATA THAT SHOWS ENDOBARRIER REDUCES HBA1C IN PATIENTS WITH TYPE 2 DIABETES  
9/16/2008
more
 
 
 
 
  FIVEPRIME INITIATES PHASE I OF FP-1039 IN PATIENTS WITH ADVANCED CANCERS  
9/8/2008
more
 
 
 
 
  COLUCID PRESENTS PHASE II RESULTS OF COL-144 AT THE EUROPEAN HEADACHE AND MIGRAINE TRUST INTERNATIONAL CONGRESS 2008  
9/5/2008
more
 
 
 
 
  REGADO BIOSCIENCES REPORTS CLINICAL RESULTS FOR REG1 ANTICOAGULATION SYSTEM AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2008  
9/4/2008
more
 
 
 
 
  CELATOR RECEIVES ORPHAN DRUG DESIGNATION FOR CPX-351  
9/4/2008
more
 
 
 
 
  ZOGENIX CLOSES $18 MILLION FINANCING WITH OXFORD FINANCE CORPORATION AND CIT HEALTHCARE LLC  
8/5/2008
more
 
 
 
 
  MARINUS APPOINTS JOHN KRAYACICH AS PRESIDENT AND CEO  
8/5/2008
more
 
 
 
 
  DAVID J. MAZZO, PH.D., JOINS REGADO BIOSCIENCES AS PRESIDENT AND CEO  
8/4/2008
more
 
 
 
 
  CELATOR RAISES SERIES C FINANCING IN EXCESS OF $22.5 MILLION  
7/28/2008
more
 
 
 
 
  ALTEA PARTNERS TRANSDERMAL PRODUCT WITH HOSPIRA  
7/2/2008
more
 
 
 
 
  COLUCID CLOSES $25 MILLION SERIES B FINANCING  
7/1/2008
more
 
 
 
 
  ZOGENIX TO PRESENT DOSEPRO RESULTS AT ANNUAL AMERICAN HEADACHE SOCIETY MEETING  
6/28/2008
more
 
 
 
 
  ALIMERA REPORTS RESULTS FROM THE THREE-MONTH INTERIM READOUT OF THE HUMAN PK MEDIDUR FA STUDY  
6/26/2008
more
 
 
 
 
  VANDA ANNOUNCES POSITIVE TOP-LINE PHASE III DATA OF TASIMELTON IN ADULTS WITH CHRONIC INSOMNIA  
6/26/2008
more
 
 
 
 
  CELL BIOSCIENCES ANNOUNCES NEW LEADERSHIP  
6/24/2008
more
 
 
 
 
  MERITAGE ACQUIRES PEDIATRIC GASTROINTESTINAL PROGRAM FROM VERUS PHARMACEUTICALS  
6/16/2008
more
 
 
 
 
  MERITAGE PHARMA CLOSES $22.5 MILLION SERIES A FINANCING  
6/16/2008
more
 
 
 
 
  GIDYNAMICS PRESENTS INITIAL RESULTS AT ADA  
6/13/2008
more
 
 
 
 
  GENVAULT CORPORATION RAISES $13 MILLION OF VENTURE FINANCING  
6/9/2008
more
 
 
 
 
  OREXIGEN: CONTRAVE MAY REVERSE THE INCIDENCE OF METABOLIC SYNDROME  
6/7/2008
more
 
 
 
 
  VANDA AND LABCORP COLLABORATE TO OFFER GENETIC TESTS  
6/5/2008
more
 
 
 
 
  CELATOR REPORTS POSITIVE PHASE 2 DATA FOR CPX-1 IN COLORECTAL CANCER  
6/3/2008
more
 
 
 
 
  VENTIRX APPOINTS DR. ELLIOT GROSSBARD TO BOARD OF DIRECTORS  
5/20/2008
more
 
 
 
 
  FIVEPRIME AND PFIZER ENTER ONCOLOGY AND DIABETES COLLABORATION  
5/20/2008
more
 
 
 
 
  NOVALAR RECEIVES FDA APPROVAL FOR ORAVERSE  
5/12/2008
more
 
 
 
 
  CELATOR PHARMACEUTICALS APPOINTS SCOTT JACKSON AS CEO  
5/9/2008
more
 
 
 
 
  FIVE PRIME REPORTS DISCOVERY OF IL-34, A NOVEL CYTOKINE  
5/8/2008
more
 
 
 
 
  ESPERION THERAPEUTICS COMPLETES $22.75M SERIES A FINANCING  
5/1/2008
more
 
 
 
 
  NUON THERAPEUTICS INC. COMPLETES $27M SERIES B FINANCING  
4/28/2008
more
 
 
 
 
  OREXIGEN COMPLETES ENROLLMENT OF SECOND PHASE III CONTRAVE TRIAL  
4/22/2008
more
 
 
 
 
  TARGETRX COMPLETES $9.6MM FINANCING ROUND  
4/7/2008
more
 
 
 
 
  ORQIS MEDICAL PRESENTS MOMENTUM TRIAL RESULTS AT ACC  
4/1/2008
more
 
 
 
 
  DIOBEX ANNOUNCES PRESENTATION OF SCIENTIFIC POSTER AT ANNUAL MEETING OF AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS  
4/1/2008
more
 
 
 
 
  FDA ACCEPTS ZOGENIX NDA FILING  
3/19/2008
more
 
 
 
 
  DIOBEX AND CAMURUS SIGN LICENSE AGREEMENT FOR THE DEVELOPMENT OF DIO-901 IN FLUIDCRYSTAL EXTENDED RELEASE TECHNOLOGY  
3/18/2008
more
 
 
 
 
  ALIMERA SCIENCES CLOSES $30 MILLION SERIES C FINANCING  
3/18/2008
more
 
 
 
 
  SCIELE PHARMA ACQUIRES TWINJECT FROM VERUS PHARMACEUTICALS  
3/13/2008
more
 
 
 
 
  PHARMION SHAREHOLDERS APPROVE ACQUISTION BY CELGENE  
3/6/2008
more
 
 
 
 
  REVA MEDICAL RAISES $42M  
12/10/2007
more
 
 
 
 
  CELGENE TO ACQUIRE PHARMION FOR $2.9B  
11/19/2007
more
 
 
 
 
  CELGENE TO ACQUIRE PHARMION FOR $2.9B  
11/19/2007
more
 
 
 
 
  CELGENE TO ACQUIRE PHARMION FOR $2.9B  
11/19/2007
more
 
 
 
 
  CELGENE TO ACQUIRE PHARMION FOR $2.9B  
11/19/2007
more
 
 
 
 
  CELGENE TO ACQUIRE PHARMION FOR $2.9B  
11/19/2007
more
 
 
 
 
  NOVALAR RAISES $30M IN SERIES D FINANCING  
10/26/2007
more
 
 
 
 
  OREXIGEN RELEASES SUMMARY OF POSITIVE PHASE 2B CONTRAVE RESULTS IN OBESITY  
10/21/2007
more
 
 
 
 
  VERUS DIVESTS PEDIATRIC ASTHMA PROGRAM TO ASTRAZENECA  
10/8/2007
more